<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872416</url>
  </required_header>
  <id_info>
    <org_study_id>FAHG20120926A</org_study_id>
    <secondary_id>FAHGuangzhou012</secondary_id>
    <nct_id>NCT01872416</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer</brief_title>
  <official_title>A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer: Single Center, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there is no standard second-line treatment of refractory and relapsed SCLC,&#xD;
      topotecan, gemcitabine, paclitaxel, irinotecan and drugs such as cyclophosphamide second-line&#xD;
      treatment of small cell lung cancer currently being explored, Anthracycline antibiotics is a&#xD;
      cell cycle non-specific anticancer drugs could inhibit the synthesis of DNA, DNA and&#xD;
      dependent RNA, its wide antitumor spectrum, widely used in malignant hematologic diseases and&#xD;
      lung cancer and other solid tumors. Jacot W, et al evaluated epirubicin combined with&#xD;
      ifosfamide (EI) for treatment of refractory and recurrent SCLC in 70 cases, the objective&#xD;
      response rate (ORR) reached 21.4%, including 1 cases of complete remission, 10% other&#xD;
      patients obtained stable disease (SD), all the patients had a median survival of 3.9 months,&#xD;
      most (71%) patients with neutropenia, platelet count and anemia are also common, showed that&#xD;
      EI treatment of refractory and relapsed SCLC is effectively controlled, toxicity.&#xD;
&#xD;
      In view of epirubicin combined with ifosfamide (EI) scheme is effective and safety in the&#xD;
      treatment of refractory and relapsed SCLC, the investigators will use liposomal doxorubicin&#xD;
      plus ifosfamide second-line treatment of refractory and relapsed small cell lung cancer, may&#xD;
      obtain better tumor remission rate, improve the prognosis of the patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the investigators will evaluate the overall response rate (complete and partial responses) in&#xD;
      first-line treatment failure or relapse after first-line therapy SCLC treated with Pegylated&#xD;
      liposomal doxorubicin and ifosfamide We will evaluate the progression-free survival (PFS) and&#xD;
      overall survival (OS) i in receiving first-line treatment failure or relapse after first-line&#xD;
      therapy SCLC treated with Pegylated liposomal doxorubicin and ifosfamide&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 5 months</time_frame>
    <description>participants will be followed for the duration of hospital stay, an expected average of 5 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival(PFS）</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 5 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 10 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Refractory and relapsed SCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposomal Doxorubicin Combined With ifosfamide</intervention_name>
    <description>Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer</description>
    <arm_group_label>Refractory and relapsed SCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients &gt;=18 years of age&#xD;
&#xD;
          2. the histological diagnosis of small cell lung cancer;&#xD;
&#xD;
          3. Patients who had first-line treatment failure or relapse after first-line therapy;&#xD;
&#xD;
          4. enough tumor tissue specimens for molecular marker analysis;&#xD;
&#xD;
          5. Measurable disease by RECIST criteria&#xD;
&#xD;
          6. ECOG performance status of &lt;=2.&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. Laboratory values as follows:: ANC ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; HB ≥&#xD;
             90g/L; serum bilirubin ≤ 1.5 upper limit of normal (N); ALT/AST≤ 2N (in patients with&#xD;
             liver metastases :ALT/AST≤ 5N) creatinine≤1.25 N;and clearance rate of creatinine ≥&#xD;
             60mLl/min; proteinuria &lt; 2+, or were detected in 24 hour urine protein, protein&#xD;
             content is ≤1g&#xD;
&#xD;
          9. Patient must be accessible for treatment and follow-up&#xD;
&#xD;
         10. All patients must be able to understand the nature of the study and give written&#xD;
             informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. mixed small cell lung cancer;&#xD;
&#xD;
          2. patients had a previous diagnosis of malignant tumor;&#xD;
&#xD;
          3. HIV infection;&#xD;
&#xD;
          4. A history of cardiac disease as defined by malignant hypertension, unstable angina,&#xD;
             congestive heart failure of &gt; grade 2 per New York Heart Association (NYHA) criteria,&#xD;
             myocardial infarction within the previous 6 months, or symptomatic cardiac&#xD;
             arrhythmias.&#xD;
&#xD;
          5. patients had the motor or sensory neurons lesions/symptoms of NCI - CTC AE &gt; 1;&#xD;
&#xD;
          6. patients had serious active infections;&#xD;
&#xD;
          7. patients were allergic to ifosfamide or liposomal doxorubicin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianxing He, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianxing He, MD</last_name>
    <phone>+86-20-83062808</phone>
    <email>hejx@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yalei Zhang, Master degree</last_name>
    <phone>+86-20-83062821</phone>
    <email>yayazhang2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>he First Affiliated Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxing He, MD</last_name>
      <phone>+86-20-83062808</phone>
      <email>hejx@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yalei Zhang, Master</last_name>
      <phone>+86-20-83062821</phone>
      <email>yayazhang2004@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jianxing He</investigator_full_name>
    <investigator_title>The First Affiliated Hospital of Guangzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>Refractory and relapsed small cell lung cancer</keyword>
  <keyword>Liposomal Doxorubicin</keyword>
  <keyword>ifosfamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

